Username or E-mail:

Password:

EULA

Forgot Password

Username:

E-mail:

Password:

EULA

Forgot Password

Already a Member

Username or E-mail

Send Forgot Mail

Back to Login

EULA

İrtibat

Logout

ZYME

Closed

Zymeworks Inc. Common Stock

8.66

-0.19 (-2.15%)

Last Update: 18 Apr 2024 23:00:00

Yesterday: 8.85

Day's Range: 8.6 - 8.925

Send

inforMate

When Written:

Zymeworks Inc. is a clinical-stage biopharmaceutical company that develops multifunctional biotherapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ZW25, is a bispecific antibody that targets two different epitopes of the HER2 protein, which is overexpressed in many types of cancer. ZW25 is currently being evaluated in clinical trials for the treatment of breast, gastric, and ovarian cancers.

Zymeworks Inc. common stock is listed on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME". As of September 2021, the company had a market capitalization of approximately $2.6 billion. The stock has experienced significant volatility since its initial public offering (IPO) in 2017, with highs of over $60 per share and lows of under $10 per share. As of September 2021, the stock was trading at around $34 per share.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.

(0)

Send

inforMate

When Written:

Zymeworks Inc. is a Canadian biotechnology company that develops multifunctional biotherapeutics for the treatment of cancer and other diseases. Its common stock is listed on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME". As of September 2021, the company has a market capitalization of approximately $3.5 billion. Zymeworks' lead product candidate, ZW25, is a bispecific antibody that targets two different epitopes of the HER2 protein, which is overexpressed in various cancers. The company also has a pipeline of other bispecific antibodies and antibody-drug conjugates in preclinical and clinical development. Zymeworks was founded in 2003 and is headquartered in Vancouver, British Columbia, Canada.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.

(0)

Send

Contact with us

Mail:

Message:

Cancel

Send

IP Adresiniz:18.118.200.86

YASAL UYARI:

   Finansal veriler Unicorn Data Services A.Ş. tarafından sağlanmaktadır. Hisse senedi verileri 15 dakika gecikmeli, Tahvil-Bono-Repo özet verileri de 15 dakika gecikmelidir. Burada sunulan yatırım bilgi, yorum ve tavsiyeler kesinlikle yatırım danışmanlığı hizmeti kapsamında değildir. Yatırım danışmanlığı hizmeti; aracı kurumlar, portföy yönetim şirketleri ve mevduat kabul etmeyen bankalarla müşteri arasında imzalanan yatırım danışmanlığı sözleşmesi çerçevesinde sunulmaktadır. Burada yer alan yorum ve tavsiyeler, ilgili kişilerin kişisel görüşlerine dayanmaktadır. Bu görüşler, mali durumunuz ve risk/getiri tercihlerinizle uygun olmayabilir.

   Bu nedenle, yalnızca burada yer alan bilgilere dayanarak yatırım kararı verirken beklentilerinize uygun sonuçlar elde edemeyebilirsiniz. Web sitemizde veya kullanılan kaynaklarda olabilecek hata ve eksikliklerden, bilgilerin kullanımından doğrudan veya dolaylı olarak kaynaklanabilecek yatırımcıların zararlarından, kar kayıplarından, manevi zararlardan ve üçüncü kişilerin uğrayabileceği zararlardan dolayı Noktacom Medya İnternet Hizmetleri San. ve Tic. A.Ş. hiçbir şekilde sorumlu tutulamaz.

   BİST (Borsa İstanbul) isim ve logosu "Koruma Marka Belgesi" altında korunmakta olup, izinsiz kullanılamaz, kopyalanamaz ve değiştirilemez. BİST adı altında açıklanan tüm bilgilerin telif hakları tamamen BİST'e aittir ve tekrar yayınlanması kesinlikle yasaktır.

PRICE DISCLAIMER:

   The information provided on our website [https://www.fiyaat.com] (the "Site") regarding stock market prices and foreign exchange rates is for general informational purposes only. While we strive to provide accurate and up-to-date information, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained on the Site.

   Any reliance you place on such information is strictly at your own risk. We strongly advise you to conduct your own research and seek professional advice before making any investment or trading decisions based on the information provided on our Site.

   We do not guarantee the accuracy, timeliness, performance, completeness, or suitability of the information and materials found or offered on the Site for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors, and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

   In no event will we be liable for any loss or damage including, without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of or in connection with the use of the Site.

   Through the Site, you may be able to link to other websites that are not under our control. We have no control over the nature, content, and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorsement of the views expressed within them.

   Every effort is made to keep the Site up and running smoothly. However, we take no responsibility for, and will not be liable for, the Site being temporarily unavailable due to technical issues beyond our control.